Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Maryland for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Maryland only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Maryland (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Steven Klein (NPI 1730185471)

Field	Value
Entity Type	Individual
Organization	Steven Klein
Address	346 Mill St
City	Hagerstown
State	MD
ZIP	21740
Taxonomy	Rheumatology Physician
NPI Enumerated	June 27, 2005

Payer Source	Total Paid
Medicare	$2.6M
Medicaid	$0

Key Findings

This provider’s practice is heavily oriented toward in-office administration of biologic and injected therapies: the largest single revenue contributor is J0129 (abatacept) with $966.5K in Medicare revenue and J0897 (denosumab) with $515.2K, and J1745 (infliximab) also appears in the top three. The presence of multiple high-volume J‑codes and frequent administration codes (96413, 96365, 96372) is consistent with an infusion/biologics service line supporting chronic rheumatologic and bone disease management rather than a pure office-consult only model.

Revenue is highly concentrated in a small set of drugs: the top 3 Medicare codes by revenue account for 67.4% of this provider's total Medicare revenue, with J0129 alone representing 37.4% ($966.5K) of the $2.6M Medicare lifetime revenue. This concentration indicates that fluctuations in utilization, reimbursement, or supply for a few biologics could materially affect overall Medicare revenue.

In public payer mix terms the provider is effectively single‑payer: reported lifetime Medicare revenue is $2.6M while there is no Medicaid billing on file. The absence of Medicaid activity suggests limited exposure to state program payment rules and that contracting or network strategies with commercial payers will likely determine broader payor diversification needs.

The provider ranks as a national outlier on several products, indicating a dominant role for select codes: J0897 ranks #110 of 10057 providers nationally (99th percentile; extreme outlier, far above typical national volume) and J0129 ranks #56 of 1221 (95th percentile; notably above typical national volume). By contrast, J1745 ranks #97 of 1352 (93th percentile; typical, unremarkable volume), so the practice’s competitive strength appears concentrated on particular biologics rather than uniformly across all infused therapies.

Office evaluation-and-management activity is also high relative to peers: 99214 generated 1.2K claims and $111.5K (4.3% of Medicare revenue) and ranks #7799 of 479517 providers nationally (98th percentile; extreme outlier, far above typical national volume). This elevated E/M volume aligns with ongoing outpatient management and follow-up visits commonly required for patients receiving chronic biologic therapies.

Infusion and ancillary administration codes show above-average utilization, supporting an infusion-capable operation: 96365 (538 claims, $28K) ranks #340 of 8873 (96th percentile; typical, unremarkable volume), 96413 (434 claims, $46K) ranks #963 of 7514 (87th percentile; typical, unremarkable volume), and 96372 (1K claims, $11.4K) ranks #356 of 58224 (99th percentile; extreme outlier, far above typical national volume). These patterns point to substantial infusion nursing and chair time as material components of practice capacity and cost structure.

The practice shows a marked focus on bone-health services in addition to rheumatology infusions: 77085 (bone density) produced $17.6K and ranks #51 of 1287 (96th percentile; notably above typical national volume), J3111 (romosozumab) and J3489 (zoledronic acid) are also present with J3489 ranking #53 of 3032 (98th percentile; extreme outlier, far above typical national volume). Together these codes suggest a bundled clinical focus on osteoporosis assessment and infused bone therapies that complements rheumatologic care.

This is a long‑tenured, specialty practice profile: the NPI was enumerated 2005-06-27 (~21 years ago) and lifetime Medicare revenue is $2.6M. Given the combination of long tenure, concentrated biologic revenue, high E/M ranks, and no Medicaid billing on file, payers and providers evaluating network value should view this entity as a Medicare-focused infusion and outpatient rheumatology provider with concentrated drug exposure and specific areas of clinical strength.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

24 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	28,430	$30	$966.5K
J0897	Injection, denosumab, 1 mg	28,620	$20	$515.2K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	9,870	$30	$256.6K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	60,400	$1	$241.6K
J3262	Injection, tocilizumab, 1 mg	37,560	$10	$187.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,160	$100	$111.5K
J1602	Injection, golimumab, 1 mg, for intravenous use	9,350	$10	$102.8K
J3111	Injection, romosozumab-aqqg, 1 mg	7,980	$10	$63.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	430	$110	$46K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	540	$50	$28K

Showing 1–10 of 24

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 24 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Maryland Distribution

Steven Klein — 8 of 24 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Maryland

Full comparison — all codes billed, vs. state median

24 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	2	40	6,060	$30	$290.2K
J0717	8	30	41,000	$1	$225.7K
J3111	29	30	17,430	$10	$192.3K
J3262	10	20	28,780	$1	$159K
J0897	6	340	3,600	$20	$114.4K
J1745	4	40	2,810	$30	$109K
J1602	11	30	8,300	$10	$102.8K
96413	42	230	200	$110	$29.6K
99214	380	10,270	150	$90	$24.1K
20611	138	200	50	$90	$9K

Showing 1–10 of 24

Related Providers

Other providers that share a Tax Identification Number (TIN) with Steven Klein, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mary Howell	MD	Internal Medicine Physician	$1.6M	$0
Adnan Kiani	IA	Rheumatology Physician	$685.6K	$0

Nearby Providers

Other providers in the same ZIP code as Steven Klein, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Dr. David M. Vieth 2, P.C.	MD	General Practice Dentistry	$0	$77.8M
Potomac Case Management Services, Inc.	MD	Case Management Agency	$0	$28M
Phoenix Health Center LLC	MD	Methadone Clinic	$507.7K	$21.4M
Awakenings Recovery Center, LLC	MD	Substance Abuse Rehabilitation Facility	$0	$19.8M
Qualitycare Internet, LLP	MD	Mental Health Counselor	$0	$19.4M
Walnut Street Community Health Center, Inc.	MD	Federally Qualified Health Center (FQHC)	$0	$19.3M
Board Of Education Of Washington County	MD	Local Education Agency (LEA)	$0	$19.1M
Center For Pain Management, LLC	MD	Interventional Pain Medicine Physician	$0	$18.9M
Metro Treatment Of Maryland LP	MD	Community/Behavioral Health Agency	$361K	$16.6M
The Western Maryland Counseling Center	MD	Community/Behavioral Health Agency	$0	$16.5M

Steven Klein — Billing Profile & Reimbursement Data

Sign up for Steven Klein — Billing Profile & Reimbursement Data policy alerts

Steven Klein — Billing Profile & Reimbursement Data

Sign up for Steven Klein — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References